Form 4: Janux Therapeutics Director Sheila Gujrathi Reports Acquisition of Shares and Stock Options

Director Sheila Gujrathi reports acquisition of 2,500 shares of common stock and 8,350 stock options in Janux Therapeutics.

Summary

• On June 26, 2024, Sheila Gujrathi, a director of Janux Therapeutics, acquired 2,500 shares of common stock and 8,350 stock options.
• The 2,500 shares were granted as restricted stock units (RSUs) and will vest on the earlier of June 26, 2025, or the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• The stock options, with an exercise price of $39.8, will vest in equal monthly installments over the 12 months following June 26, 2024, but will be fully vested by the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• Following these transactions, Gujrathi directly owns 110,528 shares of Janux Therapeutics common stock and 8,350 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director is generally a positive sign, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of RSUs and stock options is contingent upon the Reporting Person's continuous service, suggesting an incentive for continued involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company.

Stakeholder Impact

• The reported transactions may have a minor positive impact on shareholder sentiment.

Key Dates